{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:23:02Z","timestamp":1783084982963,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11522-6","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:34:27Z","timestamp":1781087667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can alterations in miR-21, miR-1, and miR-224 expression predict personalized medicine chemotherapy in non-small cell lung cancer?"],"prefix":"10.1007","volume":"53","author":[{"given":"Firoozeh","family":"Faridanjahromi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1805-4261","authenticated-orcid":false,"given":"Alireza","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Jafarinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"yavarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"11522_CR1","doi-asserted-by":"publisher","unstructured":"Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L et al (2023) Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncology. ;9(4):465\u201372.https:\/\/doi.org\/10.1001\/jamaoncol.2022.7826","DOI":"10.1001\/jamaoncol.2022.7826"},{"key":"11522_CR2","doi-asserted-by":"publisher","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. ;74(3):229\u201363.https:\/\/doi.org\/10.3322\/caac.21834","DOI":"10.3322\/caac.21834"},{"issue":"4","key":"11522_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4]","volume":"13","author":"G Luo","year":"2025","unstructured":"Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J et al (2025) Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respiratory Med 13(4):348\u2013363. https:\/\/doi.org\/10.1016\/S2213-2600(24)00428-4]","journal-title":"Lancet Respiratory Med"},{"key":"11522_CR4","doi-asserted-by":"publisher","unstructured":"Wu Y, Yuan M, Wang C, Chen Y, Zhang Y, Zhang J, Corrigendum (2023) T lymphocyte cell: A pivotal player in lung cancer. Front Immunol. ;14:1166352.https:\/\/doi.org\/10.3389\/fimmu.2023.110277","DOI":"10.3389\/fimmu.2023.110277"},{"key":"11522_CR5","doi-asserted-by":"publisher","unstructured":"Tang FH, Wong HYT, Tsang PSW, Yau M, Tam SY, Law L et al (2025) Recent advancements in lung cancer research: a narrative review. Transl Lung Cancer Res. ;14(3):975\u201390.https:\/\/doi.org\/10.21037\/tlcr-24-979","DOI":"10.21037\/tlcr-24-979"},{"key":"11522_CR6","doi-asserted-by":"publisher","unstructured":"Loren P, Saavedra N, Saavedra K, De Godoy Torso N, Visacri MB, Moriel P et al (2022) Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review. Frontiers in Pharmacology. ;Volume 13\u20132022.https:\/\/doi.org\/10.3389\/fphar.2022.831099","DOI":"10.3389\/fphar.2022.831099"},{"issue":"5","key":"11522_CR7","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.3390\/ijms23052805]","volume":"23","author":"B Smolarz","year":"2022","unstructured":"Smolarz B, Durczy\u0144ski A, Romanowicz H, Szy\u0142\u0142o K, Hogendorf P (2022) MiRNAs in cancer (Review of Literature). Int J Mol Sci 23(5):2805. https:\/\/doi.org\/10.3390\/ijms23052805","journal-title":"Int J Mol Sci"},{"issue":"9","key":"11522_CR8","doi-asserted-by":"publisher","first-page":"e10608","DOI":"10.1016\/j.heliyon.2022.e10608","volume":"8","author":"R Ranasinghe","year":"2022","unstructured":"Ranasinghe R, Mathai ML, Zulli A (2022) Cisplatin for cancer therapy and overcoming chemoresistance. Heliyon 8(9):e10608. https:\/\/doi.org\/10.1016\/j.heliyon.2022 Collection 2022 sep]","journal-title":"Heliyon"},{"key":"11522_CR9","doi-asserted-by":"publisher","first-page":"105430","DOI":"10.1016\/j.jddst.2024.105430]","volume":"93","author":"H Tian","year":"2024","unstructured":"Tian H, Cheng L, Liang Y, Lei H, Qin M, Li X et al (2024) MicroRNA therapeutic delivery strategies: A review. J Drug Deliv Sci Technol 93:105430. https:\/\/doi.org\/10.1016\/j.jddst.2024.105430]","journal-title":"J Drug Deliv Sci Technol"},{"key":"11522_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111528]","author":"BM Hussen","year":"2021","unstructured":"Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafouri-Fard S (2021) MicroRNA: A signature for cancer progression. Biomed Pharmacother. https:\/\/doi.org\/10.1016\/j.biopha.2021.111528]. 138:111528.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"11522_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.21037\/tlcr-22-742","volume":"12","author":"B Tomasik","year":"2023","unstructured":"Tomasik B, Skrzypski M, Bie\u0144kowski M, Dziadziuszko R, Jassem J (2023) Current and future applications of liquid biopsy in non-small-cell lung cancer\u2014a narrative review. Translational Lung Cancer Res 12(3):594\u2013614. https:\/\/doi.org\/10.21037\/tlcr-22-742 2023 Mar 9]","journal-title":"Translational Lung Cancer Res"},{"key":"11522_CR12","doi-asserted-by":"publisher","unstructured":"Bartoszewska E, Misi\u0105g P, Czapla M, Rakoczy K, Tomecka P, Filipski M et al (2025) The Role of microRNAs in Lung Cancer: Mechanisms, Diagnostics and Therapeutic Potential. International Journal of Molecular Sciences. ;26(8):3736.https:\/\/doi.org\/10.3390\/ijms26083736","DOI":"10.3390\/ijms26083736"},{"key":"11522_CR13","doi-asserted-by":"publisher","unstructured":"Dai S, Li F, Xu S, Hu J, Gao L (2023) The important role of miR-1-3p in cancers. J Transl Med. ;21(1).https:\/\/doi.org\/10.1186\/s12967-023-04649-8","DOI":"10.1186\/s12967-023-04649-8"},{"key":"11522_CR14","doi-asserted-by":"publisher","unstructured":"Safa A, Bahroudi Z, Shoorei H, Majidpoor J, Abak A, Taheri M et al (2020) miR-1: A comprehensive review of its role in normal development and diverse disorders. Biomedicine & Pharmacotherapy. ;132:110903.https:\/\/doi.org\/10.1016\/j.biopha.2020.110903 2020 oct 20]","DOI":"10.1016\/j.biopha.2020.110903"},{"key":"11522_CR15","doi-asserted-by":"publisher","unstructured":"Li Z, Zhang H, Chen Z, Wu G, Guo W, Li Y (2025) MicroRNA\u201321: A potential therapeutic target in lung cancer (Review). Int J Oncol. ;67(2):67.https:\/\/doi.org\/10.3892\/ijo.2025.5773","DOI":"10.3892\/ijo.2025.5773"},{"key":"11522_CR16","doi-asserted-by":"publisher","first-page":"175233","DOI":"10.1016\/j.ejphar.2022.175233","volume":"932","author":"T Akhtarkhavari","year":"2022","unstructured":"Akhtarkhavari T, Bahrami AR, Matin MM (2022) Downregulation of miR-21 as a promising strategy to overcome drug resistance in cancer. Eur J Pharmacol 932:175233. https:\/\/doi.org\/10.1016\/j.ejphar.2022","journal-title":"Eur J Pharmacol"},{"key":"11522_CR17","doi-asserted-by":"publisher","unstructured":"Han H, Pan B, Liang F, Wu L, Liu X, Yang Y et al (2022) MiR-224 promotes lymphatic metastasis by targeting ANGPTL1 in non-small-cell lung carcinoma. Cancer Biomarkers. ;34(3):431\u201341.https:\/\/doi.org\/10.3233\/CBM-210376","DOI":"10.3233\/CBM-210376"},{"issue":"1","key":"11522_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3967\/bes2023.144]","volume":"37","author":"LM Yang","year":"2024","unstructured":"Yang LM, Zheng Q, Liu XJ, Li XX, Lim V, Chen Q et al (2024) Exosome-Transmitted miR-224-5p promotes colorectal cancer cell proliferation via targeting ULK2 in p53-Dependent manner. Biomed Environ Sci 37(1):71\u201384. https:\/\/doi.org\/10.3967\/bes2023.144","journal-title":"Biomed Environ Sci"},{"key":"11522_CR19","doi-asserted-by":"publisher","unstructured":"Tao Y, Zhang J, Chen L, Liu X, Yao M, Zhang H (2021) LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p\/PBX3 signaling circuit. Cell Death & Disease. ;12.https:\/\/doi.org\/10.1038\/s41419-021-03767-9","DOI":"10.1038\/s41419-021-03767-9"},{"key":"11522_CR20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.omtn.2021.01.028]","volume":"23","author":"J Zhou","year":"2021","unstructured":"Zhou J, Wang H, Sun Q, Liu X, Wu Z, Wang X et al (2021) miR-224-5p-enriched exosomes promote tumorigenesis by directly targeting androgen receptor in non-small cell lung cancer. Mol Therapy - Nucleic Acids 23:1217\u20131228. https:\/\/doi.org\/10.1016\/j.omtn.2021.01.028]","journal-title":"Mol Therapy - Nucleic Acids"},{"key":"11522_CR21","doi-asserted-by":"publisher","unstructured":"Ceylan A, Artac M, Kocak M, Arta\u00e7 H (2024) Epidermal growth factor receptor and programmed cell death-1 expression levels in peripheral T cell subsets of patients with non-small cell lung cancer. Scandinavian journal of immunology. ;100:e13398.https:\/\/doi.org\/10.1111\/sji.13398","DOI":"10.1111\/sji.13398"},{"key":"11522_CR22","doi-asserted-by":"publisher","unstructured":"Yamaguchi H, Hsu J-M, Yang W-H, Hung M-C (2022) Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nature Reviews Clinical Oncology. ;19(5):287\u2013305.https:\/\/doi.org\/10.1038\/s41571-022-00601-9","DOI":"10.1038\/s41571-022-00601-9"},{"key":"11522_CR23","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.adcanc.2024.100125]","volume":"11","author":"P Shiri Aghbash","year":"2024","unstructured":"Shiri Aghbash P, Mehdizadeh F, Pourbeiragh G, Yazdani Y, Bannazadeh Baghi H, Jafari Sales A et al (2024) PD-L1 and PD-1 in immune regulation and their implications in blood cancers. Adv Cancer Biology - Metastasis 11:100125. https:\/\/doi.org\/10.1016\/j.adcanc.2024.100125","journal-title":"Adv Cancer Biology - Metastasis"},{"key":"11522_CR24","doi-asserted-by":"publisher","unstructured":"Chen K, Ge L, Liu G (2023) Integrated in silico\u2013in vitro rational design of oncogenic EGFR-derived specific monoclonal antibody-binding peptide mimotopes. Journal of Bioinformatics and Computational Biology. ;21(02):2350007.https:\/\/doi.org\/10.1142\/S0219720023500075","DOI":"10.1142\/S0219720023500075"},{"key":"11522_CR25","doi-asserted-by":"publisher","unstructured":"Kishore1 RR, VP. Correlation between ALK, ROS1 Biomarkers and EGFR Oncogene Mutations in Lung Tumours: Our Observations in an Apex Oncopathology Laboratory. Asian Pacific Journal of Cancer Biology. 04\/28\/2023;8(2):111\u20137.https:\/\/doi.org\/10.31557\/APJCB (2023) 8.2.111]","DOI":"10.31557\/APJCB"},{"key":"11522_CR26","doi-asserted-by":"publisher","unstructured":"Laface C, Maselli FM, Santoro AN, Iaia ML, Ambrogio F, Laterza M et al (2023) The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies. Pharmaceutics. ;15(6):1604.https:\/\/doi.org\/10.3390\/pharmaceutics15061604","DOI":"10.3390\/pharmaceutics15061604"},{"key":"11522_CR27","doi-asserted-by":"publisher","unstructured":"Minerva BA, Verma S, Chander G, Jamwal RS, Sharma B et al (2023) Cisplatin-based combination therapy for cancer. Journal of Cancer Research and Therapeutics. ;19(3):530\u20136.https:\/\/doi.org\/10.4103\/jcrt.jcrt_792_22","DOI":"10.4103\/jcrt.jcrt_792_22"},{"key":"11522_CR28","doi-asserted-by":"publisher","unstructured":"Yan H, Tang S, Tang S, Zhang J, Guo H, Qin C et al (2022) miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential. Frontiers in Pharmacology. ;Volume 13\u20132022.https:\/\/doi.org\/10.3389\/fphar.2022.949566","DOI":"10.3389\/fphar.2022.949566"},{"key":"11522_CR29","doi-asserted-by":"publisher","unstructured":"Liang X, Wu Q, Wang Y, Li S (2023) MicroRNAs as early diagnostic biomarkers for non\u2013small cell lung cancer (Review). Oncol Rep. ;49(1):8.https:\/\/doi.org\/10.3892\/or.2022.8445","DOI":"10.3892\/or.2022.8445"},{"key":"11522_CR30","doi-asserted-by":"publisher","unstructured":"Metcalf GAD (2024) MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances. Oncogene. ;43(28):2135\u201342.https:\/\/doi.org\/10.1038\/s41388-024-03076-3","DOI":"10.1038\/s41388-024-03076-3"},{"key":"11522_CR31","doi-asserted-by":"publisher","unstructured":"Michael A, Ancuta J, George AC (2025) MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy. Cancer Drug Resistance. ;8:64.https:\/\/doi.org\/10.20517\/cdr.2025.146","DOI":"10.20517\/cdr.2025.146"},{"key":"11522_CR32","doi-asserted-by":"publisher","unstructured":"Tylden ES, Delgado AB, Lukic M, Moi L, Busund LR, Pedersen MI et al (2024) Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies. Sci Rep. ;14(1):25022.https:\/\/doi.org\/10.1038\/s41598-024-75557-0","DOI":"10.1038\/s41598-024-75557-0"},{"key":"11522_CR33","doi-asserted-by":"publisher","unstructured":"Hua L, Zhu G, Wei J (2018) MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy. Cell Biol Int. ;42(9):1240\u20139.https:\/\/doi.org\/10.1002\/cbin.10995","DOI":"10.1002\/cbin.10995"},{"key":"11522_CR34","doi-asserted-by":"publisher","unstructured":"Hiraku Y, Watanabe J, Kaneko A, Ichinose T, Murata M (2021) MicroRNA expression in lung tissues of asbestos-exposed mice: upregulation of miR-21 and downregulation of tumor suppressor genes Pdcd4 and Reck. J Occup Health 63(1). https:\/\/doi.org\/10.1002\/1348-9585.12282","DOI":"10.1002\/1348-9585.12282"},{"key":"11522_CR35","doi-asserted-by":"publisher","unstructured":"Du J, Qian J, Zheng B, Xu G, Chen H, Chen C (2021) miR-21-5p is a Biomarker for Predicting Prognosis of Lung Adenocarcinoma by Regulating PIK3R1 Expression. Int J Gen Med. ;14:8873\u201380.https:\/\/doi.org\/10.2147\/IJGM.S337149","DOI":"10.2147\/IJGM.S337149"},{"key":"11522_CR36","doi-asserted-by":"publisher","unstructured":"Jiang HG, Dai CH, Xu YP, Jiang Q, Xia XB, Shu Y et al (2021) Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non-small cell lung cancer. Oncol Lett. ;22(5):792.https:\/\/doi.org\/10.3892\/ol.2021.13053","DOI":"10.3892\/ol.2021.13053"},{"key":"11522_CR37","doi-asserted-by":"publisher","unstructured":"Tian J, He Y, Zhang Z, Zhu Y, Ren H, Zhang L et al (2025) miR-224-5p Suppresses Non-Small Cell Lung Cancer via IL6ST-Mediated Regulation of the JAK2\/STAT3 Pathway. Thorac Cancer. ;16(2):e15516.https:\/\/doi.org\/10.1111\/1759-7714.15516","DOI":"10.1111\/1759-7714.15516"},{"key":"11522_CR38","doi-asserted-by":"publisher","unstructured":"Zhang J, Han L, Yu J, Li H, Li Q (2021) miR-224 aggravates cancer-associated fibroblast-induced progression of non-small cell lung cancer by modulating a positive loop of the SIRT3\/AMPK\/mTOR\/HIF-1\u03b1 axis. Aging (Albany NY). ;13(7):10431\u201349.https:\/\/doi.org\/10.18632\/aging.202803","DOI":"10.18632\/aging.202803"},{"key":"11522_CR39","doi-asserted-by":"publisher","unstructured":"Oh S, Lee S, Cheon I, Ahn YH (2025) miR-224 activates cancer-associated fibroblasts to enhance lung cancer cell migration and invasion by targeting Akirin1. Sci Rep. ;15(1):3050.https:\/\/doi.org\/10.1038\/s41598-024-82189-x","DOI":"10.1038\/s41598-024-82189-x"},{"key":"11522_CR40","doi-asserted-by":"publisher","unstructured":"Attathikhun M, Jurj A, Calin GA (2025) MicroRNAs as key regulators of cancer drug resistance: insights and future directions in chemotherapy, targeted-therapy, radiotherapy, and immunotherapy. Cancer Drug Resistance. ;8:64.https:\/\/doi.org\/10.20517\/cdr.2025.146","DOI":"10.20517\/cdr.2025.146"},{"key":"11522_CR41","doi-asserted-by":"publisher","unstructured":"MacDonagh L, Gallagher MF, Ffrench B, Gasch C, Gray SG, Reidy M et al (2021) MicroRNA expression profiling and biomarker validation in treatment-na\u00efve and drug resistant non-small cell lung cancer. Translational Lung Cancer Research. ;10(4):1773\u201391.https:\/\/doi.org\/10.21037\/tlcr-20-959","DOI":"10.21037\/tlcr-20-959"},{"key":"11522_CR42","doi-asserted-by":"publisher","unstructured":"Liu CH, Liu SH, Lai YL, Cho YC, Chen FH, Lin LJ et al (2022) Using bioinformatics approaches to identify survival-related oncomiRs as potential targets of miRNA-based treatments for lung adenocarcinoma. Comput Struct Biotechnol J. ;20:4626\u201335.https:\/\/doi.org\/10.1016\/j.csbj.2022.08.042","DOI":"10.1016\/j.csbj.2022.08.042"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11522-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:00:54Z","timestamp":1783083654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11522-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11522"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11522-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7255974\/v1","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The affiliation of the first author, Firoozeh Faridanjahromi, and thethird author, Mojtaba Jafarinia has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The National Committee of Ethics in Biomedical Research reviewed and approved the studies involving human participants under the ethics code IR.IAU.M.REC.1400.007. The participants provided informed consent for their involvement in this study, and their data were collected and used in accordance with ethical guidelines. The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of competing interest"}}],"article-number":"930"}}